Kringle Pharma, Inc.
Fiscal Year 2026 (September) Full-Year Earnings Presentation
For the fiscal year ended September 2026, net loss widened. Revenue increased due to API supply to Claris and a one-time contract payment from Maruishi Pharmaceutical, but operating loss expanded substantially due to increased R&D expenses and the upfront recording of commercial formulation development costs for vocal fold scarring. For fiscal 2027, revenue is expected to increase, but R&D spending is expected to remain elevated.
Key Figures
- Revenue: 442 million yen
- Net Loss Attributable to Owners of Parent: -813 million yen
- Cash and Cash Equivalents at Period-End: 1,053 million yen
AI要約
Overview of Results
For the fiscal year ended September 2026, revenue increased due to API supply to Claris and receipt of a one-time contract payment, while higher R&D expenses and the recording of costs for the commercial formulation development for vocal fold scarring weighed heavily, leading to a significant expansion of operating loss. Ordinary loss has trended lower but remains in deficit. Strengthening manufacturing capabilities for U.S. and overseas expansion and preparations for an additional Phase III trial are ongoing.
Outlook and Funding
For the fiscal year ending September 2027, revenue is expected to increase, but the impact of higher R&D spending and organizational strengthening costs will continue. Funding will utilize the "TIP" program to prepare for the U.S. Phase III trial and accelerate overseas expansion. The allocation of funds is clarified to realize the three-pronged strategy (two domestic product launches, overseas expansion, and indication expansion).
Revenue Trend
Operating Income (Loss) Trend
Net Income Trend
Cash and Cash Equivalents
Breakdown of Use of Funds
Kringle Pharma, Inc.
Company overview · Stock price · Financial data · All IR
